Researchers Explore Existing Medicines as Kidney Cancer Treatments

Kidney cancer can spread beyond the kidney and become difficult to treat. Researchers are exploring whether medicines already used for other conditions could offer additional treatment options. Repurposing drugs may shorten development timelines because their properties and some safety information are already known, but effectiveness against cancer still requires direct clinical testing.

This review examines existing drugs with potential activity against renal cell carcinoma, the most common type of kidney cancer. Examples include metformin and simvastatin, several antimicrobial and antiparasitic medicines, aspirin, celecoxib, acetazolamide, and disulfiram. It also discusses drugs targeting mTOR, including temsirolimus and everolimus, which already have established roles in treating advanced kidney cancer rather than representing entirely new repurposing candidates.

The authors describe several ways these medicines may interfere with cancer biology. These include disrupting signals that support tumor growth, changing cellular energy regulation, blocking cellular recycling, and triggering damaging chemical reactions or mitochondrial dysfunction. The abstract highlights pathways such as PI3K/AKT/mTOR and AMPK, but provides no numerical estimates of tumor shrinkage, survival benefit, or treatment response for any individual drug.

For clinicians, the review offers a map of treatment hypotheses and possible research directions, not evidence that familiar prescriptions should routinely be added to cancer care. For patients, the practical message is to discuss appropriate clinical trials with an oncology team rather than start these medicines independently. Safety in another condition does not establish safety in cancer treatment combinations.

This summary is based on the abstract only. The abstract does not explain how studies were selected, assess their quality, or clearly separate laboratory findings from human trial results. It also supplies no dosing recommendations or comparative safety data. Consequently, the review supports further investigation, but cannot establish which repurposed drugs improve outcomes, which patients might benefit, or whether any proposed combination outperforms current standard treatment options.